Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-264-4280
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees54
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions
What is Rhythm Pharmaceuticals' stock symbol?
Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
How were Rhythm Pharmaceuticals' earnings last quarter?
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) posted its quarterly earnings data on Monday, July, 29th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.36. View Rhythm Pharmaceuticals' Earnings History.
When is Rhythm Pharmaceuticals' next earnings date?
What price target have analysts set for RYTM?
6 brokerages have issued 12 month price objectives for Rhythm Pharmaceuticals' stock. Their predictions range from $34.00 to $43.00. On average, they anticipate Rhythm Pharmaceuticals' share price to reach $38.6667 in the next year. This suggests a possible upside of 87.7% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals.
What is the consensus analysts' recommendation for Rhythm Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals.
What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
- 1. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and our $34 target price on RYTM shares after the company reported its 2Q19 financials and business update. As we highlighted in our recent upgrade note (here), at the current share price, we believe there is a favorable risk/reward ahead of the Phase 3 data readouts for setmelanotide in POMC and LEPR deficiency obesities which are expected in the coming weeks. We believe both Phase 3 studies will be positive and in our homerun" scenario the stock could move up to the low ~$40 range. Additionally, we believe the 4Q19 update from management on its ongoing patient identification efforts for POMC/LEPR and other MC4R pathway disorders remain an unappreciated catalyst investors should be tracking." (7/29/2019)
- 2. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (7/17/2019)
- 3. Needham & Company LLC analysts commented, "Rhythm reported 1Q19 financial results today and we spoke w/ mgmt for an update. Top-line results from setmelanotide Phase 3 trials in POMC and LEPR are expected 3Q19. We continue to expect positive outcomes based on impressive Phase 2 data. Rhythm is still opening sites in the setmelanotide Phase 3 trial in pts w/ but mgmt reiterated guidance for completing enrollment in 2H19 and results in 2H20. The company is assessing 6-12 other rare genetic obesity disorders for potential inclusion in the ongoing Phase 2 basket trial. An update is expected later this yr. Mgmt also plans to share more data from GO-ID obesity DNA sequencing study and TEMPO rare genetic obesity registry later this yr. BUY." (5/5/2019)
Has Rhythm Pharmaceuticals been receiving favorable news coverage?
News stories about RYTM stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Rhythm Pharmaceuticals.
Are investors shorting Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals saw a decline in short interest in July. As of July 31st, there was short interest totalling 1,458,100 shares, a decline of 14.4% from the June 30th total of 1,702,900 shares. Based on an average trading volume of 229,800 shares, the short-interest ratio is presently 6.3 days. Currently, 7.6% of the company's stock are short sold. View Rhythm Pharmaceuticals' Current Options Chain.
Who are some of Rhythm Pharmaceuticals' key competitors?
Some companies that are related to Rhythm Pharmaceuticals include HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA), Genmab A/S (GMAB), PTC Therapeutics (PTCT), Amicus Therapeutics (FOLD), The Medicines (MDCO), Agios Pharmaceuticals (AGIO), Myokardia (MYOK), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), Xencor (XNCR), Intercept Pharmaceuticals (ICPT), Uniqure (QURE), Portola Pharmaceuticals (PTLA) and Zogenix (ZGNX).
What other stocks do shareholders of Rhythm Pharmaceuticals own?
Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the folowing people:
- Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
- Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
- Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
- Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
- Mr. Simon D. Kelner, Chief HR Officer (Age 46)
When did Rhythm Pharmaceuticals IPO?
(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.
Who are Rhythm Pharmaceuticals' major shareholders?
Rhythm Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (9.56%), Janus Henderson Group PLC (9.54%), BlackRock Inc. (5.53%), Vanguard Group Inc. (3.44%), Price T Rowe Associates Inc. MD (3.11%) and TimesSquare Capital Management LLC (1.61%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, Der Ploeg Leonardus HT Van, James E Flynn, Keith Michael Gottesdiener, Orbimed Advisors Llc and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals.
Which institutional investors are selling Rhythm Pharmaceuticals stock?
RYTM stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, EcoR1 Capital LLC, Alps Advisors Inc., Morgan Stanley, Northern Trust Corp, Wells Fargo & Company MN and BNP Paribas Arbitrage SA. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Der Ploeg Leonardus HT Van and Keith Michael Gottesdiener. View Insider Buying and Selling for Rhythm Pharmaceuticals.
Which institutional investors are buying Rhythm Pharmaceuticals stock?
RYTM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., University of Notre Dame DU Lac, Price T Rowe Associates Inc. MD, Rice Hall James & Associates LLC, Vanguard Group Inc., DekaBank Deutsche Girozentrale, Charles Schwab Investment Management Inc. and Rock Springs Capital Management LP. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals.
How do I buy shares of Rhythm Pharmaceuticals?
Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rhythm Pharmaceuticals' stock price today?
One share of RYTM stock can currently be purchased for approximately $20.60.
How big of a company is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a market capitalization of $710.91 million. The company earns $-74,060,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.View Additional Information About Rhythm Pharmaceuticals.
What is Rhythm Pharmaceuticals' official website?
How can I contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]
MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
